---
title: "Lytix Biopharma Wins Shareholder Backing for NOK 30m Offering and Conversion to Public Company"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273730660.md"
description: "Lytix Biopharma AS has received shareholder approval for a NOK 30 million offering and will convert to a public limited liability company, changing its name to Lytix Biopharma ASA. The extraordinary general meeting also approved amendments to the articles of association, elected Darlene Deptula-Hicks to the board until 2027, and set the subscription period for the new share offering from January 27 to February 10, 2026. These actions aim to strengthen Lytix's capital base and governance as it advances its oncology pipeline."
datetime: "2026-01-26T17:03:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273730660.md)
  - [en](https://longbridge.com/en/news/273730660.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273730660.md)
---

# Lytix Biopharma Wins Shareholder Backing for NOK 30m Offering and Conversion to Public Company

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Lytix Biopharma AS ( (DE:6BG) ) has provided an announcement.

Lytix Biopharma has secured shareholder approval for a series of corporate actions, including a subsequent offering of up to NOK 30 million directed at eligible existing shareholders, the conversion from a private to a public limited liability company with a name change to Lytix Biopharma ASA, and an authorization for the board to increase share capital. The extraordinary general meeting also approved amendments to the company’s articles of association, elected Darlene Deptula-Hicks as an additional board member until 2027, and set the subscription period for the new share offering from 27 January to 10 February 2026, steps that collectively strengthen Lytix’s capital base, governance and public-market profile as it advances its oncology pipeline.

**More about Lytix Biopharma AS**

Lytix Biopharma is an Oslo-based clinical-stage biotech company developing cancer immunotherapies derived from host-defense peptides. Its lead candidate, LTX-315, is a first-in-class oncolytic molecule intended to boost anti-cancer immunity, supported by a broader pipeline targeting multiple tumor types both as monotherapy and in combination regimens.

**YTD Price Performance:** -9.31%

**Average Trading Volume:** 87,676

**Current Market Cap:** NOK672.8M

For an in-depth examination of 6BG stock, go to TipRanks’ Overview page.

### Related Stocks

- [LSBCF.US](https://longbridge.com/en/quote/LSBCF.US.md)
- [LIXT.US](https://longbridge.com/en/quote/LIXT.US.md)

## Related News & Research

- [Orkla (OB:ORK) Margin Improvement Challenges Cautious Earnings Narratives Heading Into Q1 2026](https://longbridge.com/en/news/287134604.md)
- [Nekkar lifts treasury stake to 9.8% under renewed NOK 100m buy-back](https://longbridge.com/en/news/286731769.md)
- [Assessing BlueNord (OB:BNOR) Valuation After Its US$400 Million Refinancing Deal](https://longbridge.com/en/news/287098111.md)
- [Health Rounds: Widely used asthma drug may improve performance of cancer immunotherapies](https://longbridge.com/en/news/286957357.md)
- [City of Hope reports phase 1 ABBV-969 prostate cancer drug shows 45% response rate](https://longbridge.com/en/news/287275827.md)